Logos Global Management
BEAM icon

Logos Global Management’s Beam Therapeutics BEAM Stock Holding History

Logos Global Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-500,000
Closed -$12.2M – 52
2024
Q3 		$12.2M Buy
+500,000
New +$12.9M 1.32% 26

Other funds holding BEAM

Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.5B AUM 50.54% 1-Year Est. Return
Arch Venture Management
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Logos Global Management's BEAM Position: Q4 2024 in Review

Logos Global Management sold out of Beam Therapeutics (BEAM) in Q4 2024, closing a stake of 500,000 shares — an estimated $12.2M sold.

Logos Global Management first reported a position in BEAM in Q3 2024 and held it in 1 quarter. The position peaked at $12.2M in Q3 2024. 231 funds tracked by Wall St. Rank hold BEAM as of Q4 2024.

  • Logos Global Management reported no remaining Beam Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Logos Global Management sold 500,000 Beam Therapeutics shares in Q4 2024, an estimated $12.2M.
  • Logos Global Management first reported a position in Beam Therapeutics in Q3 2024 and held it in 1 quarter.
  • Logos Global Management's Beam Therapeutics position peaked at $12.2M in Q3 2024.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2024.

Based on Logos Global Management's 13F filing for Q4 2024, filed 14 Feb 2025.